Results 41 to 50 of about 650,104 (308)

[How should hormone therapy for castration-resistant prostate cancer be continued?] [PDF]

, 2012
After an average of 18-36 months under androgen suppression therapy by surgical castration, LHRH, and steroidal or non-steroidal antiandrogens, almost all patients with metastatic prostate cancer show PSA progression as a sign of androgen-independent but
Spahn, M, Krebs, M
core   +1 more source

Gene Expression Profiling Analysis Reveals Putative Phytochemotherapeutic Target for Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2019
Prostate cancer is the leading cause of cancer death among men globally, with castration development resistant contributing significantly to treatment failure and death.
Solomon Oladapo Rotimi, Oluwakemi Anuoluwapo Rotimi, Abdulkadir Ayo Salako, Paul Jibrin, Jelili Oyelade, Emeka E. J. Iweala   +5 more
doaj   +1 more source

A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. [PDF]

, 2015
Recent advances in understanding the mechanisms underlying the development and progression of castration resistant prostate cancer from androgen-sensitive prostate cancer have provided new avenues exploring efficacious therapies in a disease which is the
Rosario, D.J., Rosario DJ, Khabazhaitajer M, Greasley, R., Khabazhaitajer, M., Greasley R   +5 more
core   +1 more source

Darolutamide For Castration-Resistant Prostate Cancer.

OncoTargets and therapy, 2019
The treatment landscape of advanced prostate cancer continues to evolve rapidly, with newer and more active drugs being used in earlier phases of the disease based on improved overall survival. After adoption of docetaxel for metastatic castration-sensitive disease, large trials with next-generation androgen receptor-signaling inhibitors (abiraterone ...
Bastos,Diogo A, Antonarakis,Emmanuel S
openaire   +3 more sources

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

, 2013
BACKGROUND: Median overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) was 13-16 mo in the predocetaxel era. Prognostic nomograms for survival estimation in CRPC were constructed prior to the introduction of docetaxel
Pezaro, Carmel, Omlin, Aurelius, Thompson, Emilda, Sandhu, Shahneen, Maier, Gal, de Bono, Johann, Attard, Gerhardt, Bianchini, Diletta, Olmos, David, Ferraldeschi, Roberta, Parker, Chris, Mukherji, Deborah, Mulick Cassidy, Amy   +12 more
core   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Alteration in expression and subcellular localization of the androgen receptor- regulated FAM111A protease is associated with emergence of castration resistant prostate cancer

Neoplasia: An International Journal for Oncology Research
The androgen receptor (AR) is a pivotal regulator of growth and survival of prostate cancer (PCa) and the majority of lethal castration-resistant prostate cancers (CRPC) remain reliant on AR signaling.
Maria Malvina Tsamouri, Stephen J. Libertini, Salma Siddiqui, Maitreyee K. Jathal, Blythe P. Durbin-Johnson, Clifford G. Tepper, Eva Corey, Jun Luo, Kenneth A. Iczkowski, Paramita M. Ghosh, Maria Mudryj   +10 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Influence of statins in metastatic castration-resistant prostate cancer patients treated with new antiandrogen therapies: a systematic review and meta-analysis

Einstein (São Paulo), 2022
Objective To evaluate whether the addition of statins to the new antiandrogens (enzalutamide or abiraterone) affects overall survival in patients with metastatic castration-resistant prostate cancer.
Renato Mariano Jr, Kevin Lima Tavares, Renato Panhoca, Marcus Sadi   +3 more
doaj   +1 more source

Re: The Role of MicroRNA in Castration-Resistant Prostate Cancer

, 2016
EDITORIAL COMMENT Castration-resistant prostate cancer (CRPC) arises when hormone refractory prostate cancer growth occurs in a castrate androgen level environment. Although the mechanism is not fully understood, the androgen receptor (AR) has emerged
Fehmi Narter
core   +1 more source